Миокардиальная дисфункция при прогрессирующей мышечной дистрофии Дюшенна/Беккера: современные методы лечения

Рожкова А.Б.; Грознова О.С.; Ковалёв И.А.

Миокардиальная дисфункция при прогрессирующей мышечной дистрофии Дюшенна/Беккера: современные методы лечения

Авторы: Рожкова А.Б., Грознова О.С., Ковалёв И.А.

Тип статьи: Обзоры

Библиографическая ссылка: Детские болезни сердца и сосудов. 2024; 21 (4): 275-284

Цитировать как: Рожкова А.Б., Грознова О.С., Ковалёв И.А. . Миокардиальная дисфункция при прогрессирующей мышечной дистрофии Дюшенна/Беккера: современные методы лечения. Детские болезни сердца и сосудов. 2024; 21 (4): 275-284. DOI:

Скачать (Download)

Литература

Thada P.K., Bhandari J., Forshaw K.C., Umapathi K.K. Becker Muscular Dystrophy. Treasure Island (FL): StatPearls; 2024. PMID: 32310552
Salari N., Fatahi B., Valipour E., Kazeminia M., Fatahian R., Kiaei A. et al. Global prevalence of Duchenne and Becker muscular dystrophy: a systematic review and meta-analysis. J. Orthop. Surg. Res. 2022; 17 (1): 1–12. DOI: 10.1186/s13018-022-02996-8
Birnkrant D.J., Bushby K., Bann C.M., Apkon S.D., Blackwell A., Brumbaugh D. et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018; 17 (3): 251–267. DOI: 10.1016/S1474-4422(18)30024-3
Verma S., Goyal P., Beam C., Shah D. Turner syndrome and Duchenne Muscular Dystrophy. Muscle & Nerve. 2017; 56 (2): 12–15. DOI: 10.1002/mus.25618
Mccaffrey T., Guglieri M., Murphy A.P., Bushby K., Johnson A., Bourke J.P. Cardiac involvement in female carriers of Duchenne or Becker muscular dystrophy. Muscle Nerve. 2018; 55: 810–818. DOI: 10.1002/mus.25445
Duan D., Goemans N., Takeda S., Mercuri E., Aartsma-Rus A. Duchenne muscular dystrophy. Nat. Rev. Dis. Primers. 2021; 7 (1): 1–34. DOI: 10.1038/s41572-021-00248-3
Bladen C.L., Salgado D., Monges S., Foncuberta M.E., Kekou K., Kosma K. et al. The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum. Mutat. 2015; 36 (4): 395–402. DOI: 10.1002/humu.22758
Wilson D.G.S., Tinker A., Iskratsch T. The role of the dystrophin glycoprotein complex in muscle cell mechanotransduction. Commun. Biol. 2022; 5 (1): 1–18. DOI: 10.1038/s42003-022-03980-y
Tidball J.G., Welc S.S., Wehling-Henricks M. Immunobiology of inherited muscular dystrophies. Compr. Physiol. 2018; 8 (4): 1313–1356. DOI: 10.1002/cphy.c170052
Bushby K., Finkel R., Birnkrant D.J., Case L.E., Clemens P.R., Cripe L. et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010; 9 (1): 77–93. DOI: 10.1016/S1474-4422(09)70271-6
Adorisio R., Mencarelli E., Cantarutti N., Calvieri C., Amato L., Cicenia M. et al. Duchenne dilated cardiomyopathy: cardiac management from prevention to advanced cardiovascular therapies. J. Clin. Med. 2020; 9 (10): 3186. DOI: 10.3390/jcm9103186
Fayssoil A., Abasse S., Silverston K. Cardiac involvement classification and therapeutic management in patients with Duchenne muscular dystrophy. J. Neuromuscul. Dis. 2017; 4 (1): 17–23. DOI: 10.3233/JND-160194
Feingold B., Mahle W.T., Auerbach S., Clemens P., Domenighetti A.A., Jefferies J.L. et al. Management of cardiac involvement associated with neuromuscular diseases. Circulation. 2017; 136: 200–231. DOI: 10.1161/CIR.0000000000000526
Зайнитдинова М.И., Смирнихина С.А., Лавров А.В., Еремин И.И., Пулин А.А. Генотерапевтические подходы к лечению миодистрофии Дюшенна. Гены и клетки. 2019; 14 (4): 6–18. DOI: 10.23868/201912026
Villa C.R., Kaddourah A., Mathew J., Ryan T.D., Wong B.L., Goldstein S.L. et al. Identifying evidence of cardio-renal syndrome in patients with Duchenne muscular dystrophy using cystatin C. Neuromuscul. Disord. 2016; 26 (10): 637–642. DOI: 10.1016/j.nmd.2016.07.010
Voleti S., Olivieri L., Hamann K., Gordish-Dressman H., Spurney C. Troponin I levels correlate with cardiac MR LGE and native T1 values in Duchenne muscular dystrophy cardiomyopathy and identify early disease progression. Pediatr. Cardiol. 2020; 41 (6): 1173–1179. DOI: 10.1007/s00246-020-02372-5
Mavrogeni S.I., Markousis-Mavrogenis G., Papavasiliou A., Papadopoulos G., Kolovou G. Cardiac involvement in Duchenne muscular dystrophy and related dystrophinopathies. Methods. Mol. Biol. 2018; 1687: 31–42. DOI: 10.1007/978-1-4939-7374-3_3
Spurney C.F., McCaffrey F.M., Cnaan A., Morgenroth L.P., Ghelani S.J., Gordish-Dressman H. et al. Feasibility and reproducibility of echocardiographic measures in children with muscular dystrophies. J. Am. Soc. Echocardiogr. 2015; 28 (8): 999–1008. DOI: 10.1016/j.echo.2015.03.003
Levy P.T., Machefsky A., Sanchez A.A., Patel M.D., Rogal S., Fowler S. et al. Reference ranges of left ventricular strain measures by two- dimensional speckle-tracking echocardiography in children: a systematic review and meta-analysis. J. Am. Soc. Echocardiogr. 2016; 29 (3): 209–225. DOI: 10.1016/j.echo.2015.11.016
Грознова О.С., Артемьева С.Б. Поражение сердечно-сосудистой системы при прогрессирующей мышечной дистрофии Беккера. Российский вестник перинатологии и педиатрии. 2013; 4: 83–87.
McNally E.M., Kaltman J.R., Benson D.W., Canter C.E., Cripe L.H., Duan D. et al. Contemporary cardiac issues in Duchenne muscular dystrophy. Circulation. 2015; 131 (18): 1590–1598. DOI: 10.1161/CIRCULATIONAHA.114.015151
Raman S.B., Hor K.N., Mazur W., Halnon N.J., Kissel J.T., He X. et al. Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014; 14: 153–161. DOI: 10.1016/S1474-4422(14)70318-7
Shaddy R., Canter C., Halnon N., Kochilas L., Rossano J., Bonnet D. et al. Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study). Am. Heart J. 2017; 193: 23–34. DOI: 10.1016/j.ahj.2017.07.006
Mullens W., Damman K., Harjola V.P., Mebazaa A., Brunner-La Rocca H.P., Martens P. et al. The use of diuretics in heart failure with congestion – a position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2019; 21 (2): 137–155. DOI: 10.1002/ejhf.1369
Das B.B. Current state of pediatric heart failure. Children (Basel). 2018; 5 (7): 88. DOI: 10.3390/children5070088
Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G.F., Coats A.J.S. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 2016; 18(8): 891–975. DOI: 10.1093/eurheartj/ehw128
D’Amario D., Amodeo A., Adorisio R., Tiziano F.D., Leone A.M., Perri G. et al. A current approach to heart failure in Duchenne muscular dystrophy. Heart. 2017; 103 (22): 1770–1779. DOI: 10.1136/heartjnl-2017-311269
Stoller D., Araj F., Amin A., Fitzsimmons C., Morlend R., Thibodeau J.T. et al. Implantation of a left ventricular assist device to provide long- term support for end-stage Duchenne muscular dystrophy-associated cardiomyopathy. ESC Heart Fail. 2017; 4 (3): 379–383. DOI: 10.1002/ ehf2.12160
Wittlieb-Weber C.A., Villa C.R., Conway J., Bock M.J., Gambetta K.E., Johnson J.N. et al. Use of advanced heart failure therapies in Duchenne muscular dystrophy. Prog. Pediatr. Cardiol. 2019; 53: 11–14. DOI: 10.1016/j.ppedcard. 2019.01.001
Buddhe S., Cripe L., Friedland-Little J., Kertesz N., Eghtesady P., Finder J. et al. Cardiac management of the patient with Duchenne muscular dystrophy. Pediatrics. 2018; 142 (2): 72–81. DOI: 10.1542/пед.2018-0333I
Лавров А.В., Заклязьминская Е.В. Генная терапия кардиомиопатий: возможности и ближайшие перспективы. Клиническая и экспериментальная хирургия. Журнал им. академика Б.В. Петровского. 2023; 11 (1): 32–46. DOI: 10.33029/2308-1198-2023-11-1-32- 46
Fortunato F., Farne M., Ferlini A. The DMD gene and therapeutic approaches to restore dystrophin. Neuromuscul. Disord. 2021; 31 (10): 1013–1020. DOI: 10.1016/j.nmd. 2021.08.004
Campbell C., Barohn R.J., Bertini E., Chabrol B., Comi G.P., Darras B.T. et al. Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy. J. Comp. Eff. Res. 2020; 9 (14): 973–984. DOI: 10.2217/cer-2020-0095
Syed Y.Y. Eteplirsen: first global approval. Drugs. 2016; 76 (17): 1699–1704. DOI: 10.1007/s40265-016-0657-1
Aartsma-Rus A., Krieg A.M. FDA approves eteplirsen for Duchenne muscular dystrophy: the next chapter in the eteplirsen saga. Nucleic. Acid. Ther. 2017; 27 (1): 1–3. DOI: 10.1089/nat.2016.0657
Heo Y.A. Golodirsen: first approval. Drugs. 2020; 80 (3): 329–333. DOI: 10.1007/s40265-020-01267-2
Long-term viltepso prevents motor function decline in DMD boys. Available at: https://musculardystrophynews.com/news/longterm-viltepso-prevents-motor-function-decline-dmd-boys/ (accessed October 8, 2024).
Shirley M. Casimersen: first approval. Drugs. 2021; 81 (7): 875–879. DOI: 10.1007/s40265-021-01512-2
Roy S., Shaw R., Samaddar S., Samanta S., Maity R., Chatterjee P. et al. Duchenne muscular dystrophy: a review on systemic paradigm approaching diagnosis to therapy. J. Genet. Syndr. Gene Ther. 2024; 15: 413. DOI: 10.35248/2157-7412.24.15.413
Hoy S.M. Delandistrogene moxeparvovec: first approval. Drugs. 2023; 83 (14): 1323–1329. DOI: 10.1007/s40265-023-01929-x
Liu H., Ding Y., Zhou Y., Jin W., Xie K., Chen L.L. CRISPR-P 2.0: an Improved CRISPR-Cas9 Tool for Genome Editing in Plants. Mol. Plant. 2017; 10 (3): 530–532. DOI: 10.1016/j.molp.2017.01.003
Hakim C.H., Wasala N.B., Nelson C.E., Wasala L.P., Yue Y., Louderman J.A. et al. AAV CRISPR editing rescues cardiac and muscle function for 18 months in dystrophic mice. JCI Insight. 2018; 3 (23): 124297. DOI: 10.1172/jci.insight.124297

Об авторах

Рожкова Анна Борисовна, аспирант, врач – детский кардиолог; ORCID
Грознова Ольга Сергеевна, д-р мед. наук, профессор, гл. науч. сотр., директор4; ORCID
Ковалёв Игорь Александрович, д-р мед. наук, профессор, советник директора; ORCID